| |
|
Relationship between antiretroviral plasma
concentration and emergence of HIV-1
resistance mutations at treatment failure.
Fabbiani M, Bracciale L, Ragazzoni E,
et al
Infection.
2011 Aug 25.
Abstract
Antiretroviral Drug Resistance in HIV-1-Infected Patients
Experiencing Persistent
Low-Level Viremia During First-Line Therapy.
Taiwo B, Gallien S, Aga E, Ribaudo H, et al
J Infect Dis.
2011 Aug;204(4):515-20.
Abstract
Low-Frequency HIV-1 Drug Resistance Mutations and Risk of
NNRTI-Based Antiretroviral
Treatment Failure: A Systematic Review and Pooled Analysis.
Li JZ, Paredes R, Ribaudo HJ, et al
JAMA. 2011 Apr 6;305(13):1327-35.
Abstract
Effect of transmitted drug resistance on virological and
immunological response to
initial combination antiretroviral therapy for HIV
(EuroCoord-CHAIN joint project):
a European multicohort study.
Wittkop L, Günthard HF, de Wolf F, et al
Lancet Infect Dis.
2011 Feb 25
Abstract
FULL-TEXT PDF ARTICLE
Update of the Drug Resistance Mutations in HIV-1: December
2010.
Johnson VA, Brun-Vezinet F, Clotet B,
Top HIV Med.
2010 Dec;18(5):156-63.
Paper |
The Association Between Primary Antiretroviral Resistance
and HAART Virologic
Failure
in a Developing Set.
Gagliani LH, Alkmim Maia WT,
et al
AIDS Res Hum Retroviruses.
2010 Oct 26
Abstract |
FULL-TEXT
ARTICLE
A comparative analysis of HIV drug resistance interpretation
based on short Reverse
Transcriptase sequences versus full sequences.
Steegen K, Bronze M, Van Craenenbroeck E, et al
AIDS Res Ther. 2010
Oct 15;7(1):38.
Paper |
Assessing subtype and drug-resistance-associated mutations among
antiretroviral-treated HIV-infected patients.
Hamkar R, Mohraz M, Lorestani S, et al
AIDS.
2010 Jul;24 Suppl 2:S85-91
Abstract |
Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive
Patients
Initiating Combination Antiretroviral Therapy.
[No authors listed]
Clin Infect Dis. 2010 Mar
30.
Abstract |
Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs
in
HIV-1-Infected Patients with Virological Failure.
Llibre JM, Schapiro JM, Clotet B
Clin
Infect Dis. 2010 Feb 8.
Abstract |
Connection Domain Mutations in
Treatment-Experienced Patients in the OPTIMA Trial.
Dau B, Ayers D, Singer J, .et al
J Acquir Immune Defic Syndr.
2010 Feb 3
Abstract |
Detecting and understanding combinatorial mutation patterns responsible for
HIV drug resistance.Z
hang J, Hou T, Wang W, Liu JS.
Proc Natl Acad Sci U S A.
2010 Jan 11.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Clinical Management Of HIV-1 Resistance.
Paredes R, Clotet B.
Antiviral Res. 2009 Oct 3.
Abstract |
New developments in HIV drug resistance.
Cane PA.
J Antimicrob Chemother.
2009 Sep;64 Suppl 1:i37-40.
Abstract |
Antiretroviral Drug Resistance in Human Immunodeficiency Virus
Type 2 (HIV-2).
Ntemgwa ML, Toni TD, Brenner BG, et al
|
Antimicrob Agents Chemother. 2009 May
26
Abstract |
A Comparison of Interpretation by Three Different HIV Type 1
Genotypic Drug Resistance
Algorithms Using
Sequences from Non-Clade B HIV Type 1 Strains.
Kandathil AJ, Kannangai R, Abraham OC, et al
AIDS Res Hum Retroviruses.
2009 Mar 17.
Abstract
|
A WEEK IN REVIEW FEATURED REPORT
Antiretroviral Therapy in HIV-Infected Patients with
Multidrug-Resistant Virus: Applying the Guidelines
to Practice.
Kaplan SS, Mounzer KC.
AIDS Patient Care STDS.
2008 Dec;22(12):931
Abstract
|
The Relationship Between Resistance and Adherence in
Drug-Naive Individuals Initiating HAART Is
Specific to Individual Drug Classes
Tam LW, Chui CK, Brumme CJ, et al
J Acquir Immune Defic Syndr. 2008 Oct 3
Abstract
|
A WEEK IN REVIEW FEATURED
REPORT
Emerging resistance profiles of newly approved
antiretroviral drugs.
Daar ES.
Top HIV Med. 2008 Oct-Nov;16(4):110-6.
Abstract
|
Emergence of drug resistance in HIV type 1-infected patients
after receipt of first-line highly active antiretroviral
therapy: a systematic review of clinical trials.
Gupta R, Hill A, Sawyer AW, Pillay D.
Clin Infect Dis. 2008
Sep 1;47(5):712-22.
Abstract
|
Antiretroviral genotypic resistance in plasma RNA and whole
blood DNA in HIV-1 infected
patients failing HAART.
Saracino A, Gianotti N, Marangi M, et al
J Med Virol. 2008 Aug
19;80(10):1695-1706.
Abstract
|
HIV-1 Drug Resistance Mutations: an Updated Framework for the
Second Decade of HAART.
Shafer RW, Schapiro JM.
AIDS Rev. 2008 Apr-Jun;10(2):67-84.
Abstract
|
World
Health Organization/HIVResNet Drug Resistance Laboratory
Strategy.
Bertagnolio S, Derdelinckx I, Parker M, et al
Antivir Ther. 2008;13 Suppl 2:49-57.
Abstract
|
Preventing HIV antiretroviral resistance through better
monitoring of treatment adherence.
Bangsberg DR.
J Infect Dis. 2008 May 15;197 Suppl
Abstract
|
Increased Resilience to the Development of Drug Resistance
with Modern Boosted Protease Inhibitor-Based
Highly Active Antiretroviral Therapy.
Lima VD, Gill VS, Yip B, et al
J Infect Dis.
2008 May 22.
Abstract
|
The Persistence of Transmitted Drug Resistance among
Subjects with Primary HIV Infection.
Little SJ, Frost SD, Wong JK, et al
J Virol. 2008 Mar 19
Abstract |
|
|
Overcoming resistance to existing therapies in HIV-infected
patients: The role of new
antiretroviral drugs.
/font>
Perno CF, Moyle G, Tsoukas C, et al
J Med Virol.
2008 Feb 22;80(4):565-576
Abstract
|
Genotypic resistance profiles in antiretroviral-naive HIV-1
infections before and after
initiation of first-line HAART: impact of polymorphism on
resistance to therapy.
Sukasem C, Churdboonchart V, Sukeepaisarncharoen W, et al
Int J Antimicrob Agents.
2008 Jan 5
Abstract
|
|
General
Reports
Treatment
Interruption
Documents identified with this icon are in Portable Document Format (PDF)
and require the>Adobe
Acrobat Reader